27180-90-1

Upstream product

• 19924-43-7 3-methoxyphenylacetonitrile 
• 27180-89-8 6-ethylhexahydro-6-(3-methoxyphenyl)<2H>azepin-2-one 
• 343227-97-4 methyl 5-(aminomethyl)-5-(3-methoxyphenyl)heptanoate 
• 76798-14-6 methyl 5-cyano-5-(3-methoxyphenyl)heptanoate 
• 1611-75-2 2-(3-methoxyphenyl)butyronitrile 
• 3553-94-4 1-trimethylsilanyl-azepan-2-one 
• 71556-83-7 3-Ethylhexahydro-3-(3-methoxyphenyl)-2H-azepin-2-one 
• 71556-71-3 hexahydro-3-(3-methoxyphenyl)-2H-azepin-2-one 
• 105-60-2 caprolactam 

Downstream Products

• 59263-75-1 3-(3-ethylhexahydro<1H>azepine-3-yl)phenol 
• 275806-03-6 2-[3-(3-ethyl-azepan-3-yl)-phenoxy]-4-imidazol-1-ylmethyl-benzonitrile 

Relevant academic research and scientific papers

3-ETHYL-3-PHENYLAZEPANE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN

The present invention relates to 3-ethyl-3-phenylazepane derivatives having dual pharmacological activity towards both the sigma (σ) receptor and the μ- opioid receptor, to processes of preparation of such compounds, to pharmaceutical compositions compris

Dual protein farnesyltransferase-geranylgeranyltransferase-I inhibitors as potential cancer chemotherapeutic agents

A series of novel diaryl ether lactams have been identified as very potent dual inhibitors of protein farnesyltransferase (FTase) and protein geranylgeranyltransferase I (GGTase-I), enzymes involved in the prenylation of Ras. The structure of the complex formed between one of these compounds and FTase has been determined by X-ray crystallography. These compounds are the first reported to inhibit the prenylation of the important oncogene Ki-Ras4B in vivo. Unfortunately, doses sufficient to achieve this endpoint were rapidly lethal.

Inhibitors of prenyl-protein transferase

The present invention is directed to compounds which inhibit prenyl-protein transferase and particularly, the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this in

Inhibitors of prenyl-protein transferase

The present invention is directed to azepan-2-one compounds which inhibit prenyl-protein transferase, particularly farnesyl-protein transferase (Ftase), and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras.